#3: Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology
Holdings (OTC Bulletin Board: LIXT) announced today that the National
Institute of...
#2: Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr. Jie
Lu and Dr. Zhengping...
Lixte Biotechnology Holdings Announces
Filing of a New Patent Application for Cancer Therapy Based on
Targeting a Biomarker by Novel Investigational Agents
EAST SETAUKET, N.Y., Aug. 19...